reduce basal insulin when starting glp-1 receptor agonist Frontiers TrimRX | GLP-1 for Type

2 Since it is non-peptide, orforglipron avoids GI degradation barriers that limit peptides, thereby enabling once-daily administration while maintaining efficacy on glucose control, body weight, and tolerability

[DOI] [PubMed] 29.Zhang HD, Ding L, Liu K, Mi LJ, Zhang AK, Yu FY, et al

Lancet Diabetes Endocrinol (2019) 7:35667

35 The mechanisms underlying the effect of GLP-1 receptor agonists on OSA remain incompletely understood but are believed to be largely mediated through weight reduction.[45] OFF-LABEL AND INVESTIGATIONAL USES OF GLP-1RAS Investigational and off-label indications of GLP1-RAs are conditions that may have some evidence of benefit, but which currently lack FDA approval for a particular medication

In a retrospective study done by Yao et al

Effects of GLP-1 on gastric emptying, antropyloric motility, and transpyloric flow in response to a nonnutrient liquid